ArticleCancer discovery2024
TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma.
Abstract read
In one paragraph
Article in Cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Application of artificial intelligence in head and neck squamous cell carcinoma.Annals of medicine · 2026Review
- The RNA-binding protein La/SSB is associated with HNSCC progression and TFAP2C/FSCN1-linked transcriptional regulation.Oncogene · 2026Article
- Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment.Cancer immunology research · 2026Article
- Exploratory single-nucleus multiomics analysis of myeloid cell states associated with neoadjuvant chemotherapy response in pancreatic ductal adenocarcinoma.Clinical and translational medicine · 2026Article
- Spatial transcriptomics in cancer research: insights into tumorigenesis, diagnosis and therapeutics.Cell death discovery · 2026Review
- Decoding the CAF-TAM axis: multi-omics dissection and therapeutic targeting of stromal-immune crosstalk in the tumor microenvironment.Cell death & disease · 2026Review
- Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer.Cancer research · 2026Article
- The double-edged sword role of tumor-associated macrophages: preventing or causing resistance to immunotherapy.Journal of experimental & clinical cancer research : CR · 2026Review
- Ocular squamous cell carcinoma in cattle: clinicopathological and prognostic considerations.Brazilian journal of veterinary medicine · 2026Article
- Beyond density: mapping the functional landscapes of macrophage-T lymphocyte niches in the tumor microenvironment.Frontiers in immunology · 2026Review
- Novae: a graph-based foundation model for spatial transcriptomics data.Nature methods · 2025Article
- TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects.NPJ precision oncology · 2025Review
- Positive and negative roles of myeloid cells in cancer immunotherapy.Journal for immunotherapy of cancer · 2025Review
- Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.Journal for immunotherapy of cancer · 2025Article
- Advancements in proteogenomics for preclinical targeted cancer therapy research.Biophysics reports · 2025Article
- Recent advances in biomarker detection of oral squamous cell carcinoma.Frontiers in oncology · 2025Review
- Targeting of TAMs: can we be more clever than cancer cells?Cellular & molecular immunology · 2024Review
- Toward clinical applications of spatial-omics in cancer research.Nature cancer · 2024Article
- Prognostic significance of multinucleated giant cells in oral squamous cell carcinoma: A retrospective clinicopathological study.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Grégoire GessainINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0001-6800-0339
Ahmed-Amine AnzaliINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0009-0000-1186-9623
Marvin LerousseauCenter for computational biology (CBIO), Mines Paris, PSL University, Paris, France.ORCID 0000-0001-6421-708X
Kevin MulderINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0002-1568-6581
Mathilde BiedINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0009-0002-0647-8964
Anne AuperinBiostatistics and Epidemiology Office, Gustave Roussy, Oncostat INSERM 1018, Labelled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France.ORCID 0000-0003-1545-0373
Daniel StockholmPSL Research University, EPHE, Paris, France.ORCID 0000-0002-5069-5256
Nicolas SignolleExperimental and Translational Pathology Platform, AMMICa, INSERM US23/UAR3655, Gustave Roussy, Villejuif, France.ORCID 0000-0001-6222-6003
Farah SassiINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0003-2078-6795
Maria Eugenia Marques Da CostaINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0002-1498-603X
Antonin MarchaisINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0003-0954-8294
Alexandre SayadiUniversité Paris Cité, Faculté de Santé, Paris, France.ORCID 0000-0003-4377-9926
Daniela WeidnerDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0009-0008-6637-5071
Stefan UderhardtDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0002-2489-2109
Quentin BlampeyParis-Saclay University, CentraleSupélec, laboratory of Mathematics and Computer Science (MICS), Gif-sur-Yvette, France.ORCID 0000-0002-3836-2889
Sumanth Reddy NakkireddyDepartment of Artificial Intelligence and Informatics Research, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0002-7771-6782
Sophie BroutinDepartment of Pharmacology, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0001-6333-3636
Charles-Antoine DutertreINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0001-7950-3652
Pierre BussonCNRS, UMR 9018, Gustave Roussy and Université Paris-Saclay, 39, rue Camille Desmoulins, Villejuif, France.ORCID 0000-0003-1027-3400
Thomas WalterCenter for computational biology (CBIO), Mines Paris, PSL University, Paris, France.ORCID 0000-0001-7419-7879
Alix MarhicDepartment of Head and Neck Oncology, Gustave Roussy Cancer Campus Villejuif, France.ORCID 0000-0002-9437-0744
Antoine Moya-PlanaDepartment of Head and Neck Oncology, Gustave Roussy Cancer Campus Villejuif, France.ORCID 0000-0003-1260-1762
Johanne GuerlainDepartment of Head and Neck Oncology, Gustave Roussy Cancer Campus Villejuif, France.ORCID 0000-0002-2685-6726
Ingrid BreuskinDepartment of Head and Neck Oncology, Gustave Roussy Cancer Campus Villejuif, France.ORCID 0000-0001-9447-2567
Odile CasiraghiDepartment of Pathology, University Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France.ORCID 0000-0002-5920-0301
Philippe GorpheDepartment of Head and Neck Oncology, Gustave Roussy Cancer Campus Villejuif, France.ORCID 0000-0001-7604-4964
Marion ClasseDepartment of Pathology, University Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France.ORCID 0000-0002-0802-6585
Jean-Yves ScoazecExperimental and Translational Pathology Platform, AMMICa, INSERM US23/UAR3655, Gustave Roussy, Villejuif, France.ORCID 0000-0003-1604-6823
Camille BlériotINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0002-4298-2888
Florent GinhouxINSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France.ORCID 0000-0002-2857-7755
Funding
Fondation ARC pour la Recherche sur le Cancer (ARC) Recruiting International Leaders 2020Institut National Du Cancer (INCa) PRT-K 23-054
Abstract
significanceNovel individual biomarkers are needed to guide therapeutic decisions for patients with head and neck cancer. We report for the first time, granulomas of TREM2-expressing multinucleated giant macrophages in keratin-rich tumor niches, as a biomarker of favorable prognosis and developed a deep-learning model to automate its quantification on routinely stained pathological slides.
Indexed as
Biomarkers, TumorHead and Neck NeoplasmsMacrophagesMembrane GlycoproteinsReceptors, ImmunologicSquamous Cell Carcinoma of Head and NeckGiant CellsHumansPrognosisBiomarkers, TumorMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.